LM
LeMaitre Vascular, Inc.
LMAT · NASDAQ
$78.96 -1.53% (-$1.23)
1M -1.90%
Market Cap $1.83B
P/E Ratio 27.90x
Div. Yield 1.18%
ROE 16.42%
Bulios Fair Price
$48.8
38.2% downside
Current Price
$78.96
Undervalued Fair Value Overvalued
According to Bulios Fair Price, LMAT is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Moderate
6/9Valuation
41 /100
Fair P/E 27.90x
PEG 1.02x
EV/EBITDA 20.51x
Growth
96 /100
Growing EPS growth 39.41%
Book val. growth 13.63%
Rev. growth 15.58%
Profitability
100 /100
Strong Gross margin 72.90%
FCF margin 28.13%
Net margin 25.02%
Quality
63 /100
Average ROIC 9.76%
Asset turnover 0.41x
ROE 16.42%
Debt
86 /100
Low Debt/Equity 0.45x
Net debt/EBITDA 1.68x
Current ratio 16.31x
Stability
93 /100
Stable Beta 0.49x
Profitable years 6
Rev. volatility 3.53%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about LMAT
Online
Sector
Healthcare
Industry
Medical - Instruments & Supplies
CEO
George W. LeMaitre
Employees
651
Headquarters
Burlington
Upcoming events
05 NOV
Earnings
Upcoming earnings report